Tysabri is top DMT in new study

A new clinical trial which compared six disease-modifying therapies (DMTs) found that Tysabri (natalizumab) was better than the five others at reducing relapses and stopping disability worsening in people with multiple sclerosis (MS).

This was a novel simulated clinical trial in which researchers used a mathematical model to incorporate data from over 20,000 people in a global MS registry.

The second best DMT for improving outcomes was found to be Gilenya (fingolimod). Overall, Tysabri, ahead of Gilenya, is most effective in preventing relapses, disability worsening and enabling disability improvement in relapsing-remitting MS,” the researchers wrote. “However,” the team noted, “the individual use of these therapies should be also guided by specific clinical scenarios and their safety profiles, which were not evaluated in this study.”